Pentostatin in Treating Patients With Refractory Chronic Graft-Versus-Host Disease
Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Pentostatin may be effective in treating chronic graft-versus-host disease by
stopping the immune system from rejecting donor stem cells or donor white blood cells.
PURPOSE: This phase II trial is studying how well pentostatin works in treating patients with
chronic graft-versus-host disease that is refractory (not responsive) to treatment with
steroids.